Galmed Pharmaceuticals Ltd.
GLMDGalmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for liver diseases. The company's lead product candidate, Aramchol, is a bile acid derivative developed for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Galmed also explores other therapeutic options targeting liver and metabolic conditions.
Company News
Galmed Pharmaceuticals reported significant bioavailability results for Aramchol meglumine, showing 3-5 fold increase compared to previous tablets, potentially enabling once-daily dosing and reducing drug costs.
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
